BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A ...

The U.S. Department of Agriculture (USDA) will potentially announce a plan to vaccinate poultry against highly pathogenic ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Cidara Therapeutics, Inc. (CDTX) on Monday announced positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The latest edition of Poultry World is available online. In this edition we visit a former investment banker who had built a ...

Cidara Therapeutics' shares were set to rally at the opening bell after a trial of the biotechnology company's non-vaccine preventative of seasonal influenza met all key goals. In premarket trading, ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...